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Edited by Sandro SonninoAbstract PGC-1a mRNA and protein are elevated in islets
from multiple animal models of diabetes. Overexpression of
PGC-1a impairs glucose-stimulated insulin secretion (GSIS).
However, it is not well known which metabolic events lead to
upregulation of PGC-1a in the b-cells under pathophysiological
condition. In present study, we have investigated eﬀects of
chronic hyperlipidemia and hyperglycemia on PGC-1a mRNA
expression in isolated rat islets. Isolated rat islets are chronically
incubated with 0, 0.2 and 0.4 mM oleic acid/palmitic acid (free
fatty acids, FFA) or 5.5 and 25 mM glucose for 72 h. FFA
dose-dependently increases PGC-1a mRNA expression level in
isolated islets. FFA also increases PGC-1a expression in mouse
b-cell-derived bTC3 cell line. In contrast, 25 mM glucose de-
creases expression level of PGC-1a. Inhibition of PGC-1a by
siRNA improves FFA-induced impairment of GSIS in islets.
These data suggest that hyperlipidemia and hyperglycemia
regulate PGC-1a expression in islets diﬀerently, and elevated
PGC-1a by FFA plays an important role in chronic hyperlipid-
emia-induced b-cell dysfunction.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Peroxisome proliferator-activated receptor gamma (PPARc)
coactivator-1a (PGC-1a) coactives PPARc as well as most
other nuclear receptors [1]. The basic biochemical function of
PGC-1a is regulation of the program of mitochondrial biogen-
esis [2]. PGC-1a is widely expressed, including brown fat, skel-
etal muscle, liver, heart, kidney and brain [1,3,4]. PGC-1a
plays important roles in many tissues, including the regulation
of adaptive thermogenesis in brown fat and muscle [1], of mus-
cle ﬁber-type switching in muscle [5], and of gluconeogenesis in
liver [6]. Recently, it has been reported that PGC-1a mRNA
and protein were elevated in islets from multiple animal mod-
els of diabetes [7]. Overexpression of PGC-1a in islets impaired
glucose stimulated insulin secretion, suggesting that PGC-1a
may also play an important role in b-cell dysfunction [7]. It
has been well established that chronic hyperglycemia and*Corresponding author.
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they are known to cause b-cell dysfunction by speciﬁc mecha-
nisms [8]. However, it is not known whether such changes also
regulate PGC-1a expression, which might be involved in caus-
ing b-cell dysfunction.
In this study, we investigated eﬀect of chronic hyperlipid-
emia and hyperglycemia on PGC-1a mRNA expression in iso-
lated rat islets. We also studied eﬀect of chronic hyperlipidemia
on PGC-1a mRNA expression in mouse b-cell-derived bTC3
cells. More importantly, we assessed the role of PGC-1a in
FFA-induced impairment of glucose-stimulated insulin secre-
tion (GSIS) in islets by using siRNA. Furthermore, we as-
sessed eﬀect of hyperlipidemia itself, not hyperglycemia, on
PGC-1a expression in vivo by using fasting rats. We also ex-
plored the possible mechanism of FFA upregulating PGC-1a
expression by using glucagons-like peptide 1 (GLP-1) and
forskolin.2. Materials and methods
2.1. Chemicals
Cell culture medium, antibiotics, AMV reverse transcriptase, Lipo-
fectAmine transfection reagent and Taq DNA polymerase were from
Gibco Invitrogen (Carlsbad, CA, USA). Horse serum and fetal bovine
serum were from Hyclone (Logan, UT, USA). Collagenase type IV
and Ficoll 400 were from Pharmacia (Uppsala, Sweden). Oleic acid,
palmitic acid, fatty acid-free bovine serum albumin (fraction V),
GLP1 and forskolin were from Sigma (St. Louis, MO). NEFA C kit
was from Wako (Osaka, Japan). RNeasy mini kit and RNase-free
DNase set were from Qiagen (Hilden, Germany). SYBR Green dye
for real-time PCR was from Open-Tech (Shanghai, PR China). Rat
insulin ELISA kit was from Crystal Chem Inc. (Downers Grove, IL,
USA). All other reagents were of analytical grade.
2.2. Animals
Male Wistar rats (200–250 g body weight) were bred under path-
ogen-free conditions at the Animal Center, Nanjing General Hospi-
tal of Nanjing Military Command, Nanjing, PR China. They had
free access to tap water and standard pelleted chow. They were
exposed to a 12-h light (07:00–19:00 h), 12-h dark cycle. All the
procedures in animal experiments were approved by the Animal
Study Committee of Institute of Molecular Medicine, Nanjing
University.
Animals were sacriﬁced and tissues including white adipose tissue,
brown adipose tissue, heart, liver, kidney and skeletal muscles were dis-
sected and harvested immediately. All the tissues were kept in liquid
nitrogen for later use.
2.3. Preparation of albumin-bound fatty acids
Stock solution of free fatty acids (FFA) (the mixtures of oleic acid
and palmitic acid as 1:1 mol ratio) was prepared by diluting FFA in
ethanol and precipitating them with addition of NaOH (ﬁnalblished by Elsevier B.V. All rights reserved.
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gen gas, and the precipitated sodium salt was reconstituted with 0.9%
(wt/vol) NaCl and stirred at room temperature for 10 min with fatty
acid-free BSA (concentration at 20% (wt/vol) in 0.15 M NaCl). Each
solution was adjusted to pH 7.4 with NaOH and ﬁltered through a
0.22-lm ﬁlter. The concentrations of FFA were quantiﬁed using a col-
orimetric method with NEFA C kit. The stock solutions were ﬁnally
adjusted to the total concentrations of 2 or 4 mM FFA using 20% fatty
acid-free BSA and stored at 20 C protected from light in tubes evac-
uated under nitrogen gas [9].2.4. Isolation of islets
Pancreatic islets were isolated by collagenase type IV digestion as
previously described [10]. Brieﬂy, rats were anaesthetized, the pancre-
atic ducts were cannulated and injected with 2 mg/ml Type IV collage-
nase in Hanks balanced salt solution to make pancreases completely
inﬂated. The pancreases were then carefully isolated and loaded into
digestion solution containing 2 mg/ml Type IV collagenase. After
digestion at 37 C for approximately 25 min, islets were puriﬁed from
exocrine tissue by centrifugation on a discontinued Ficoll 400 gradient
and transferred to RPMI 1640 medium containing 11 mM glucose,
antibiotics (100 U/ml penicillin and 100 lg/ml streptomycin) and 10%
fetal calf serum. Islets were cultured at 37 C in a humidiﬁed atmo-
sphere containing 5% CO2/95% air for 12 h (primary culture) to re-
move exocrine and other tissues.2.5. Islets culture
Following the period of primary culture, islets were handpicked un-
der dissected stereomicroscope and transferred to tissue culture plates
(500 islets equivalents (IE) per plate). In FFA-stimulated experiments,
islets were incubated in serum-free DMEM medium (glucose 5.5 mM)
with 0.2 or 0.4 mM FFA at a ﬁxed concentration of 2% BSA for 72 h.
Equivalent amount of fatty acid-free BSA was added to the control
group. In glucose-stimulated experiments, islets were incubated in
serum-free DMEM medium, respectively, containing 5.5 or 25 mM
glucose for 72 h. We also assessed eﬀect of combination of 0.4 mM
FFA and 25 mM glucose on PGC-1a expression after 72 h incubation.
In studies of GLP-1 and forskolin, islets were incubated in serum-free
DMEM medium (glucose 5.5 mM) with 20 nM GLP-1 or 100 nM for-
skolin for 24 h.2.6. bTC3 cell culture
Mouse islet b-cell-derived bTC3 cells were cultured as monolayers in
T-ﬂasks and fed fresh DMEM medium every 2–3 days. The DMEM
medium contained 25 mM glucose and was supplemented with 15%
(v/v) horse serum, 2.5% (v/v) fetal bovine serum, and L-glutamine to
a ﬁnal concentration of 6 mM. Cultures were propagated at 37 C un-
der humidiﬁed (5% CO2/95% air) conditions. In FFA-stimulated
experiments, after preincubation overnight in the presence of 5.5 mM
glucose and 10% fetal bovine serum, cells were washed three times
and incubated in serum-free DMEM medium containing 5.5 mM glu-
cose and 0.4 mM FFA at a ﬁxed concentration of 2% BSA for 72 h.
Equivalent amount of fatty acid-free BSA was added to the control
group. Cells were then harvested and total RNA was isolated for
real-time reverse transcription-polymerase chain reaction (RT-PCR)
analysis.2.7. SiRNA transfection
Three siRNA sequences targeted on diﬀerent sites of rat PGC-1a
cDNA were designed and synthesized by Genesil (Wuhan, PR China).
A negative control sequence was also provided. SiRNA was transfec-
ted into islets by using LipofectAmine transfection reagent according
to manufactures instructions. Five hours after transfection, medium
was replaced by DMEM medium (5.5 mM glucose plus 0.4 mM
FFA). Islets were harvested for isolation of RNA 72 h after medium
replacement and analyzed PGC-1a expression level by semi-quantita-
tive RT-PCR method. RNA interfering eﬀects of three siRNA se-
quences were evaluated from the results (data not shown) and the
sequence with best interfering eﬀect (we named this sequence as S1)
was selected. This sequence is: AAGACGGATTGCCCTCATTTG.
The negative control sequence (we named this sequence as N) is:
AAGCTTCATAAGGCGCATAGC.2.8. Study of GSIS
After being isolated and primarily cultured overnight as described
above, one subset of islets was transfected with siRNA sequence S1
in DMEMmedium (5.5 mM glucose, 0.4 mM FFA). Another two sub-
sets were transfected with siRNA negative control sequence N in
DMEM (5.5 mM glucose, 0 or 0.4 mM FFA). After 72 h incubation,
all islets were washed three times with DMEM medium (5.5 mM glu-
cose). Medium-sized islets (of the same size) were used for determina-
tion of insulin release. For each of the diﬀerent conditions (chronic
incubation at 0 and 0.4 mM FFA, with transfection of N or S1), three
islets were transferred to an Eppendorf tube containing 1 ml of fresh
DMEM (5.5 or 25 mM glucose plus 0.1% gelatin) and incubated at
37 C for 1 h. Eight parallel repeats were performed for each condition.
After an hour, an aliquot of medium was frozen until insulin was mea-
sured by using a rat insulin ELISA kit.
2.9. Animal fasting study
In fasting experiments, rats were either allowed free access to food or
subjected to a 24 h fasting before being killed. A third group was fasted
for 24 h and then allowed to feed ad libitum for another 24 h before
being killed [6]. Livers and islets were isolated for RNA analysis.
2.10. Semi-quantitative reverse transcription-polymerase chain reaction
Total RNA was isolated from islets and other tissues mentioned
above by using RNeasy mini kit according to the manufacturers
instructions. Trace amount of genomic DNA was eliminated by the
treatment with RNase-free DNase. The yield and quality of the
RNA were assessed by measuring absorbance at 260 and 280 nm fol-
lowed by electrophoresis on 1.5% agarose gels. One microgram of
RNA was reverse-transcribed into cDNA by using oligo (dT)18 primers
and AMV reverse transcriptase at 42 C for 1 h in standard buﬀer. Se-
quence-speciﬁc primers for PGC-1a and the house-keeping gene b-ac-
tin were used to cDNA ampliﬁcation. The primers sequence and PCR
condition were previously described [11]. In detail, primers used to
amplify PGC-1a cDNA (GenBank Access No. AB025784) were 5 0-
CCTTTCTGAACTTGATGTGA-3 0 (sense, 146–165) and 5 0-
ATGCTCTTTGCTT-TATTGCT-30 (antisense, 603–622) and yielded
a PCR product of 477 bp. b-actin (GenBank Access No. J00691) 5 0-
TCTACAATGAGCTGCGTGTG-3 0 (sense, 1599–1618) and 5 0-
GGTCAGGATCTTCATGAGGT-30 (antisense, 2357–2376) and the
size of PCR product was 314 bp. cDNA was ampliﬁed for 34
(PGC-1a) and 25 cycles (b-actin), using the following parameters:
94 C for 30 s, 52 C (PGC-1a) and 59 C (b-actin) for 30 s and
72 C for 30 s, with a ﬁnal extension step at 72 C for 7 min. PCR
products were electrophoresed through 1.5% agarose gel, stained with
ethidium bromide and visualized under ultraviolet illumination. Band
intensity was calculated densitometrically using Quantity One-4.4.1
imaging software (Bio-Rad Laboratories). Levels of mRNA were ex-
pressed as the ratio of band intensity for PGC-1a relative to that for
b-actin.2.11. Real-time RT-PCR
cDNA synthesis and primer sequences for rat PGC-1a and b-actin
were described as above. Primers for mouse PGC-1a and b-actin were
changed according to the sequences previously reported [12]. The
sequences of the primers and the sizes of the PCR products were as
follows: 5 0-GGAGCCGTGACCACTGACA-3 0 and 5 0-TGGTTTG-
CTGCATGGTTCTG-3 0 for PGC-1a (product 176 bp); 5 0-GGT-
CATC-ACTATTGGCAACGAG-3 0 and 5 0-GTCAGCAATGCCT-
GGGTACA-3 0 for mouse b-actin (product 196 bp). PCR reactions
were carried out in a volume of 20 ll containing 2 ll of cDNA tem-
plate, 250 nM of each primer, and 1· SYBR Green dye. Incubation
steps for rat PGC-1a and b-actin were described as above. Incubation
steps for mouse PGC-1a and b-actin were 94 C for 1 min, followed by
40 cycles of 94 C for 15 s, 60 C for 5 s and 72 C for 10 s. The prod-
ucts were detected with the ABI Prism 7700 Sequence Detector (Perkin
Elmer Biosystems) and the threshold cycle values (CT) were determined
as a measure of the cycle number at which a statistically signiﬁcant in-
crease in ﬂuorescence intensity was ﬁrst detected. The RNA samples
were run triplicates for the cDNA synthesis and in the following
PCR ampliﬁcations. The abundance of the ampliﬁed DNA was
determined from the CT values and was normalized to the value for
the control gene b-actin to yield the relative abundance. The values
of PGC-1a/b-actin were normalized to that of control.
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All results are expressed as means ± S.E.M. Data were analyzed
using a one-way ANOVA followed by Fishers LSD posthoc test. Pear-
sons correlation coeﬃcient (c) was computed to explore the correla-
tions between two variables. The calculations were performed using
the SPSS/Windows version 12.5S statistical package (SPSS, Chicago,
IL, USA). In all cases a P value lower than 0.05 was considered statis-
tically signiﬁcant.3. Results
3.1. PGC-1a expression is induced by free fatty acids and
inhibited by glucose in rat islets
Following 72 h incubation, FFA dose-dependently in-
creases PGC-1a in isolated rat islets. 0.2 and 0.4 mM FFAFig. 1. Eﬀects of chronic hyperlipidemia and hyperglycemia on PGC-
1a expression in islets. (A) Islets were incubated for 72 h in DMEM
medium containing 5.5 mM glucose and diﬀerent concentrations of
FFA. Data (n = 21) are expressed as means ± S.E.M. PGC-1a expres-
sion levels are quantiﬁed as the band density ratio to b-actin. A
representative RT-PCR gel is shown (one of seven similar results). (B)
Islets were incubated for 72 h in DMEM medium containing 25 or
5.5 mM glucose. Data (n = 18) are expressed as means ± S.E.M.
*P < 0.05, **P < 0.01 compared to control using one-way ANOVA
analysis.
Fig. 2. Real-time RT-PCR results in rat islets and mouse bTC3 cells. (A) P
hyperlipidemia, or their combination. Total RNA was extracted from pooled
(n = 9) are expressed as means ± S.E.M. C, control (5.5 mM glucose, 0 mM F
0.4 mM FFA. (B) bTC3 cells were incubated for 72 h in DMEM medium (5.5
were measured by real-time PCR and quantiﬁed as the ratio of PGC-1a/b-acti
b-actin are normalized to that of control. *P < 0.05, **P < 0.01 compared tincreases PGC-1a expression to 37% and twofolds, respec-
tively (Fig. 1A). However, 72 h incubation with 25 mM glu-
cose decreases PGC-1a expression to 47% (25 vs. 5.5 mM
glucose) in islets (Fig. 1B).3.2. Real-time RT-PCR results in rat islets and mouse bTC3
cells
As shown in Fig. 2A, 0.4 mM FFA increases PGC-1a to
3.7 folds, whereas 25 mM glucose inhibits PGC-1a expression
to 17% in rat islets. Combination of 0.4 mM FFA and
25 mM glucose still down-regulates PGC-1a expression (aver-
age 79% of control). 72 h incubation with 0.4 mM FFA in-
creases PGC-1a expression to 1.6 folds in bTC3 cells (Fig.
2B).
3.3. Suppression of PGC-1a expression by siRNA improves
FFA-induced impairment of GSIS in islets
As shown in Fig. 3A, RNA interfering sequence S1 inhibits
PGC-1a expression to 44% in islets which incubated with
0.4 mM FFA. To establish whether increased PGC-1a contrib-
utes to FFA-induced impairment of GSIS, we incubated islets
with 0 or 0.4 mM FFA plus transfection of siRNA S1 for 72 h
and then assessed GSIS. As expected, islets in the control
group (chronically incubated at low glucose) released increas-
ing amounts of insulin response to increasing concentration of
glucose (1.223 ± 0.006 vs. 0.852 ± 0.039 ng/islet\h) (Fig. 3B,
ﬁrst set of bars). Following chronic hyperlipidemia, islets in-
creased basal insulin release to 1.3 folds (1.143 ± 0.181 ng/
islet\h), but were completely unresponsive to glucose stimula-
tion (Fig. 3B, second set of bars). Surprisingly, suppression of
PGC-1a expression by siRNA prevented the hyperlipidemia-
induced block in GSIS (1.435 ± 0.374 vs. 0.864 ± 0.009 ng/
islet\h, P = 0.06) (Fig. 3B, third set of bars).
3.4. Nutrition status and PGC-1a expression in islets and liver
24 h fasting signiﬁcantly increases PGC-1a expression in is-
lets (Fig. 4A) and in liver (Fig. 4B) (1.8 folds and 1.6 folds,
respectively compared with control). However, PGC-1a
expression in islets (Fig. 4A) and liver (Fig. 4B) rapidly de-
clines to the normal level if fasted rats are refed.GC-1a expression changes in islets induced by chronic hyperglycemia,
islets after 72 h incubation and subjected to real-time RT-PCR. Data
FA); G, 25 mM glucose; F, 0.4 mM FFA; G + F, 25 mM glucose plus
mM glucose) containing 0 or 0.4 mM FFA. PGC-1a expression levels
n. Data (n = 9) are expressed as means ± S.E.M. The values of PGC-1a/
o control.
Fig. 4. Fasting regulates PGC-1a expression both in islets and in liver. Rats w
24 h re-feeding. Islets and liver were isolated for mRNA analysis. Data sh
*P < 0.05 compared to control.
Fig. 3. Suppression of PGC-1a expression by siRNA improves FFA-
induced impairment of GSIS in islets. (A) SiRNA sequence S1 inhibits
PGC-1a expression in islets. Islets were transfected with S1 and the
negative control N by the standard transfection performance and
PGC-1a expression level was determined by semi-quantitative RT-
PCR. (B) Measurement of glucose stimulated insulin secretion in islets.
Islets were transfected with siRNA sequence S1 or siRNA negative
control sequence N in DMEM (5.5 mM glucose, 0 or 0.4 mM FFA).
After 72 h incubation, all islets were washed three times with DMEM
medium and medium-sized islets (of the same size) were used for
determination of insulin release. For each of the diﬀerent conditions
(chronic incubation at 0 and 0.4 mM FFA, with transfection of N or
S1), three islets were transferred to an Eppendorf tube containing 1 ml
of fresh DMEM (5.5 or 25 mM glucose plus 0.1% gelatin) and
incubated at 37 C for 1 h. Eight parallel repeats were performed for
each condition. After an hour, insulin content in an aliquot of medium
was measured by using a rat insulin ELISA kit. *P < 0.05 compared to
control (5.5 mM glucose).
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islets
Following the 24 h incubation, 20 nM GLP-1 increases
PGC-1a expression to 2.5 folds over control (Fig. 5A), and
100 nM forskolin upregulates PGC-1a expression to 1.5 folds
(Fig. 5B).4. Discussion
In the present study, we ﬁrst show that chronic exposure
(72 h) to FFA (0.2–0.4 mM) dose-dependently increases PGC-
1a expression in isolated rat islets. FFA also induces PGC-1a
expression in mouse b-cell-derived bTC3 cells. In contrast,
chronic exposure (72 h) to high glucose (25 mM) decreasesere either fed ad libitum, fasted for 24 h, or fasted for 24 h followed by
own are a representative RT-PCR gel from ﬁve sets of similar data.
Fig. 5. Eﬀects of GLP-1 and forskolin on PGC-1a expression in islets.
Islets were incubated for 24 h with 20 nM GLP-1 or 100 nM forskolin.
Data (n = 15) are shown as mean PGC-1a/b-actin mRNA band density
ratio ± S.E.M. **P < 0.01 compared to control.
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FFA and glucose regulate PGC-1a expression in islets diﬀer-
ently. More importantly, suppressing PGC-1a expression im-
proves FFA-induced impairment of GSIS in islets.
Furthermore, we ﬁnd that fasting elevates PGC-1a expression
in isolated rat islets. Finally, GLP-1 and forskolin (an activator
of adenylate cyclase) also increase PGC-1a expression.
A large body of work has established that chronic hyperlip-
idemia and hyperglycemia lead to loss of GSIS, and therefore
cause b-cell dysfunction [13]. Since insulin secretion is tightly
coupled to glucose metabolism [14], defects of mitochondrial
function or reduced activities of key glycolytic enzymes can
cause b-cell dysfunction [15]. Genetic evidences [16,17] and
animal model studies [18,19] demonstrated that b-cells from
obese and diabetic animals have mitochondrial dysfunction
and defects in some key glycolytic enzymes. However, the
molecular mechanism for hyperlipidemia- and hyperglyce-
mia-induced b-cell dysfunction is largely unknown.
PGC-1a mRNA and protein have been found to be elevated
in islets from multiple animal models of diabetes, such as ob/ob
mice and ZDF rats [7]. Adenoviral-driven overexpression of
PGC-1a in islets increases the mRNA encoding the catalytic
subunit of glucose-6-phsophatase, and reduces glucokinase,
GLUT2, and glycerol-3-phosphate dehydrogenase. Conse-
quently, it decreases ATP production due to decreased glucose
oxidation, thus impairing GSIS and causing b-cell dysfunction
[7].
In the present study, we demonstrate that chronic exposure
to elevated FFA (0.2 and 0.4 mM) dose-dependently increases
PGC-1a expression in isolated rat islets. FFA also induces
PGC-1a expression in mouse b-cell-derived bTC3 cells. Of
note, abnormally high concentration of FFA is detected in ser-
um from obese and diabetic mouse models, such as ob/ob and
db/db mice [20,21]. Given that the changes in GLUT2, glucoki-
nase, glucose-6-phosphatase and glycerol-3-phosphate dehy-
drogenase levels of pancreatic islets and of b-cells [7]
(following overexpression of PGC-1a) mirror those changes
seen in obese, diabetic ZDF rat islets [22–25], we speculate that
hyperlipidemia increases PGC-1a expression in b-cells, leading
to a suppression in glucose oxidation via decreases in glycolytic
enzymes. Therefore, elevated PGC-1a could be a key mecha-
nism for hyperlipidemia-induced b-cell dysfunction.
In order to assess the role of PGC-1a in hyperlipidemia-in-
duced b-cell dysfunction, we inhibit PGC-1a expression by siR-
NA and then measure GSIS in chronic high FFA exposed islets.
It has been shown that chronic lipid culture impairs GSIS in b-
cells [26]. In the present study, 0.4 mMFFA increases basal level
of insulin secretion, but bluntsGSIS in islets following 72 h incu-
bation, which conﬁrm the previous reports. Surprisingly, inhibi-
tion of PGC-1a by siRNA signiﬁcantly improves FFA-induced
impairment of GSIS. This is the ﬁrst time demonstrating that
inhibition of PGC-1a improves FFA-induced impairment of
GSIS in isolated islets, and PGC-1a plays an important role in
FFA-induced b-cell dysfunction in vitro. It is interesting to
check eﬀect of lacking PGC-1a on FFA-induced b-cell dysfunc-
tion in vivo by using PGC-1a knockout mice.
It is known that both hyperglycemia and hyperlipidemia im-
pair b-cell function [8], but the precise mechanisms remain un-
clear. Several studies explored the diﬀerent pathways which
inducing b-cell dysfunction by high glucose and FFA. For
example, hyperglycemia causes a posttranscriptional arrest in
the mRNA maturation of pancreas duodenum homeobox-1(PDX-1), which is a critical regulator of insulin promoter
activity [27]. Excessive oxidative phosphorylation during
anaerobic glycolysis in hyperglycemic state generates reactive
oxygen species (ROS) and makes b-cell injury [28]. Elevated
uncoupling protein 2 (UCP2) decreases ATP synthesis and
ATP/ADP ratio, thus impairs GSIS and b-cell function [29].
We have recently demonstrated that chronic hyperglycemia in-
creases UCP2 expression in islets [30]. Hyperlipidemia has dif-
ferent targets to induce b-cell dysfunction, other than the
common ones (e.g., induction of ROS production [31] and
UCP2 expression [32]) shared by hyperglycemia. For example,
it has been reported that islets exposed to FFA cause a reduc-
tion in pyruvate dehydrogenase activity in concern with a fall
of glucose oxidation, thus inhibit insulin secretion [33]. FFA is
also reported to induce b-cell apoptosis by increasing ceramide
synthesis [34] and inhibiting bcl-2 expression [35]. Further-
more, FFA leads to triglyceride accumulation in islets, which
also impairs GSIS [36]. Therefore, hyperglycemia and hyper-
lipidemia induce b-cell dysfunction through a complicated net-
work. In the present study, we demonstrate that chronic
hyperlipidemia increases PGC-1a expression in islets. Decreas-
ing of PGC-1a improves FFA-induced b-cell dysfunction. In
contrast, chronic hyperglycemia decreases PGC-1a expression
and blocks hyperlipidemia-induced PGC-1a expression. Taken
previous reports and our data together, hyperlipidemia causes
b-cell dysfunction via multiple targets, some of them are inde-
pendent to hyperglycemia-aﬀected pathways, and PGC-1a
plays an important role in FFA-induced b-cell dysfunction.
The mechanism of hyperglycemia inhibiting PGC-1a expres-
sion in islets still requires further study.
PGC-1a mRNA and protein are elevated in islets from ob/ob
mice and ZDF rats [7]. It is known that both FFA and glucose
in serum are increased in these two animal models [20,31]. We
have found that chronic high FFA, not high glucose, induced
PGC-1a mRNA levels in isolated islets. It is interesting to
know whether high FFA, by itself, increases PGC-1a expres-
sion in vivo. In order to assess the question, PGC-1a mRNA
levels have been examined in islets from fasted rats. We have
found that elevated serum FFA levels, and a decreased blood
glucose level in fasted rats (data were not shown), which is sim-
ilar to other reports [37]. PGC-1a mRNA levels are elevated in
islets after 24 h fasting, and drop down to normal level after
refed. These eﬀects of fasting and our in vitro results demon-
strate that FFA itself stimulates PGC-1a expression in islets.
Of course, fasting can trigger multiple metabolic pathways
other than increasing FFA. It cannot be excluded that some
metabolites triggered by fasting aﬀect PGC-1a expression in
vivo. Thus, a cleaner system is required for assessing the eﬀect
of FFA on PGC-1a expression in islets in vivo.
Cold exposure stimulates PGC-1a expression in brown adi-
pocytes via the cAMP system [1]. PGC-1a protein levels have
been also found to be elevated in islets by cold exposure [38].
On the other hand, early studies on the GLP-1 receptor uncov-
ered a robust stimulation of cAMP levels is induced by GLP-1,
mediated by the activation of G protein, Gs and adenylate cy-
clase [39]. Similarly, forskolin is recognized as an activator of
adenylate cyclase, and has been extensively used to increase
intracellular cAMP levels in a variety of model cell culture sys-
tems [40,41]. In the present study, we have shown that both
GLP-1 and forskolin simulates PGC-1a expression, suggesting
increase of intracellular cAMP levels upregulating PGC-1a
expressing in islets. It has been reported that long-chain
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in the b-cell [42,43]. In addition, cAMP accumulation is found
in ob/ob islets [44,45]. Thus, it is possible that chronic high
FFA increases intracellular cAMP levels, consequently stimu-
lates PGC-1a expression in islets.
In conclusion, chronic hyperlipidemia, not chronic hypergly-
cemia, increases PGC-1a expression in isolated islets. Inhibi-
tion of PGC-1a by siRNA improves FFA-induced
impairment of GSIS in islets. PGC-1a plays an important role
in hyperlipidemia-induced b-cell dysfunction.
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